Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06731907 · ClinicalTrials.gov registry record · Phase 2

A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)

A Phase 2 study of Non-Small Cell Lung Cancer, sponsored by Merck Sharp & Dohme.

Recruiting
Registry status
Phase 2
Development phase
90
Enrollment target
20
Study locations

NCT06731907: Recruiting Phase 2 study of Non-Small Cell Lung Cancer, sponsored by Merck Sharp & Dohme.

NCT06731907 is a Phase 2 study of Non-Small Cell Lung Cancer that is actively recruiting participants, run by Merck Sharp & Dohme. The registered enrollment target is 90 participants, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (86% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06731907, a Phase 2 study of Non-Small Cell Lung Cancer, is actively recruiting participants, sponsored by Merck Sharp & Dohme.

RECRUITING
Registry status
Phase 2
Development phase
90 participants
Enrollment target
20
Study locations

Study Summary

Researchers are investigating new treatments for untreated advanced non-small cell lung cancer (NSCLC), which is the most common form of lung cancer and lung cancer that has spread beyond surgical removal. Standard treatments include immunotherapy, such as pembrolizumab, and chemotherapy. This study aims to determine the effectiveness of adding other treatments, including the human epidermal growth factor receptor 3-directed antibody-drug conjugate (HER3-DXd) patritumab deruxtecan, to pembrolizumab, with or without chemotherapy. The primary goals are to assess safety and efficacy of the treatments.

Primary Outcome

ORR is defined as a confirmed complete response or partial response per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as assessed by Blinded Independent Central Review (BICR).

Conditions Studied

Non-Small Cell Lung Cancer

Interventions

  • BIOLOGICAL Pembrolizumab
  • DRUG Carboplatin
  • DRUG Pemetrexed
  • DRUG Paclitaxel
  • DRUG Nab-paclitaxel

Study Locations (20)

Other

  • European Interbalkan Medical Center-Oncology Department ( Site 0205) - Thessaloniki
  • Országos Korányi Pulmonológiai Intézet ( Site 0060) - Budapest
  • Rambam Health Care Campus ( Site 0076) - Haifa
  • Shaare Zedek Medical Center ( Site 0075) - Jerusalem
  • Meir Medical Center ( Site 0071) - Kfar Saba
  • Rabin Medical Center ( Site 0074) - Petah Tikva
  • Sheba Medical Center ( Site 0070) - Ramat Gan
  • Sourasky Medical Center ( Site 0077) - Tel Aviv

Region M. de Santiago

  • Centro de Estudios Clínicos SAGA ( Site 0162) - Santiago
  • FALP ( Site 0161) - Santiago
  • Bradfordhill ( Site 0160) - Santiago

Kentucky

  • University of Kentucky ( Site 0019) - Lexington

Maryland

  • MedStar Franklin Square Medical Center ( Site 0033) - Baltimore

North Dakota

  • Sanford Fargo Medical Center ( Site 0039) - Fargo

Pennsylvania

  • Abramson Cancer Center ( Site 0010) - Philadelphia

South Dakota

  • Sanford Cancer Center ( Site 0038) - Sioux Falls

Attica

  • THORACIC GENERAL HOSPITAL OF ATHENS "I SOTIRIA"-3rd Dept of Internal Medicine and Laboratory, Oncol ( Site 0204) - Athens

Trial Details

FieldValue
Enrollment Target 90 participants
Start Date 2025-03-30
Est. Completion 2032-03-12
Phase Phase 2
Merck Sharp & Dohme

558 total trials

What NCT06731907 shows while recruiting

NCT06731907 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (86% lower).

The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 5 interventions - of which Pembrolizumab is the first listed.

NCT06731907 names 20 study sites across 11 states, led by Other, Region M. de Santiago, Kentucky.

Frequently Asked Questions

What is clinical trial NCT06731907 about?

NCT06731907 is a clinical study titled "A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)". Researchers are investigating new treatments for untreated advanced non-small cell lung cancer (NSCLC), which is the most common form of lung cancer and lung cancer that has spread beyond surgical removal. Standard treatments include immunotherapy, such as pembrolizumab, and chemotherapy. This study...

What is the current status of trial NCT06731907?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2025-03-30. Estimated completion is 2032-03-12.

What conditions does trial NCT06731907 study?

This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.

What interventions are being tested in trial NCT06731907?

The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Carboplatin (DRUG), Pemetrexed (DRUG), Paclitaxel (DRUG), Nab-paclitaxel (DRUG).

Who is sponsoring clinical trial NCT06731907?

This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06731907 being conducted?

This trial has 20 study locations across Kentucky, Maryland, North Dakota, Pennsylvania, South Dakota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Non-Small Cell Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06731907's enrollment target sits among peer trials

90 253rd of 454 higher than 199 of 454 other Non-Small Cell Lung Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02521311 · 90 participants · Phase 2

    Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)

  • NCT02939573 · 90 participants · Phase 2

    A Randomized Multicenter Study for Isolated Skin Vasculitis

  • NCT03128879 · 90 participants · Phase 2

    Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL

  • NCT03184038 · 90 participants · NA

    Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06731907

Source: ClinicalTrials.gov NCT06731907, the US trial registry maintained by the National Library of Medicine. NCT06731907 (small enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.